Compare New York Times Co (NYT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs State Street SPDR S&P Biotech ETF — how do they compare? New York Times Co trades at $66.32 (market cap $10.74B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: New York Times Co and State Street SPDR S&P Biotech ETF are close in size by market cap, and New York Times Co pays a 1.38% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold New York Times Co for 81 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| NYT | XBI | |
|---|---|---|
Market Cap | $10.74B | $10.11B |
Volume | 2,096,352 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $85.86 | $169.55 |
52-Week Low | $54.66 | $104.99 |
Typical Hold Time | 81 Days | 38 Days |
Enterprise Value | $10.14B | — |
Dividend Yield | 1.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $66.60, up 2.62% today, reflecting strong momentum after three consecutive quarterly earnings beats. Revenue and net income have grown steadily from 2022 to 2025, with profit margins expanding to 12.17%. The stock shows a bullish technical signal overall, supported by positive cash flow trends and a declared quarterly dividend of $0.23 per share. However, a recent shareholder lawsuit alleging reporting bias introduces reputational risk.
Outlook remains positive given consistent earnings outperformance and a consensus price target of $84.00, implying significant upside. Key risks include the ongoing lawsuit, competitive pressures in digital media, and potential volatility from the AI copyright dispute with OpenAI. The company's solid fundamentals and analyst support suggest resilience, but investors should weigh legal and market challenges.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
